3.74
price up icon2.75%   0.10
after-market アフターアワーズ: 3.73 -0.01 -0.27%
loading
前日終値:
$3.64
開ける:
$3.67
24時間の取引高:
1.93M
Relative Volume:
0.45
時価総額:
$608.42M
収益:
$400.57M
当期純損益:
$9.21M
株価収益率:
93.50
EPS:
0.04
ネットキャッシュフロー:
$146.36M
1週間 パフォーマンス:
+11.31%
1か月 パフォーマンス:
-16.61%
6か月 パフォーマンス:
+240.00%
1年 パフォーマンス:
+151.01%
1日の値動き範囲:
Value
$3.56
$3.795
1週間の範囲:
Value
$3.22
$3.795
52週間の値動き範囲:
Value
$0.5271
$5.78

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Name
名前
Ironwood Pharmaceuticals Inc
Name
セクター
Healthcare (1106)
Name
電話
617-621-7722
Name
住所
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Name
職員
253
Name
Twitter
@ironwoodpharma
Name
次回の収益日
2025-02-21
Name
最新のSEC提出書
Name
IRWD's Discussions on Twitter

Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
IRWD
Ironwood Pharmaceuticals Inc
3.74 592.15M 400.57M 9.21M 146.36M 0.04
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.22 57.12B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
125.96 53.16B 9.47B 2.67B 2.28B 6.0218
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.47 47.25B 14.54B 2.22B 2.58B 0.4879
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
32.91 37.59B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
490.21 21.85B 3.13B 1.27B 1.12B 26.39

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-05 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-15 ダウングレード Jefferies Buy → Hold
2025-04-15 ダウングレード Wells Fargo Overweight → Equal Weight
2025-04-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2024-09-09 開始されました Leerink Partners Market Perform
2024-08-08 ダウングレード CapitalOne Overweight → Equal Weight
2024-01-17 開始されました Craig Hallum Buy
2023-12-14 開始されました Wells Fargo Overweight
2023-11-09 開始されました Jefferies Buy
2023-09-28 開始されました JMP Securities Mkt Outperform
2022-09-02 開始されました CapitalOne Overweight
2022-04-22 開始されました Piper Sandler Overweight
2020-09-30 ダウングレード Wells Fargo Overweight → Equal Weight
2020-06-17 開始されました Northland Capital Outperform
2019-07-10 再開されました Credit Suisse Neutral
2019-03-27 アップグレード Morgan Stanley Underweight → Equal-Weight
2019-02-25 アップグレード H.C. Wainwright Sell → Neutral
2019-01-24 アップグレード JP Morgan Underweight → Neutral
2018-11-07 ダウングレード Credit Suisse Outperform → Neutral
2018-11-07 ダウングレード JP Morgan Neutral → Underweight
2018-07-23 開始されました H.C. Wainwright Sell
2018-05-09 ダウングレード Morgan Stanley Equal-Weight → Underweight
2018-01-05 ダウングレード BofA/Merrill Buy → Underperform
2017-12-06 ダウングレード Mizuho Buy → Neutral
2017-07-21 ダウングレード JP Morgan Overweight → Neutral
2017-05-03 開始されました Wells Fargo Outperform
2017-04-07 繰り返されました Mizuho Buy
2017-02-22 繰り返されました Barclays Equal Weight
2016-11-04 繰り返されました Mizuho Buy
2016-10-24 繰り返されました Wedbush Neutral
2016-10-10 繰り返されました Mizuho Buy
2016-09-27 繰り返されました WallachBeth Hold
すべてを表示

Ironwood Pharmaceuticals Inc (IRWD) 最新ニュース

pulisher
04:07 AM

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - itemonline.com

04:07 AM
pulisher
09:46 AM

US Stocks Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn

09:46 AM
pulisher
Mar 02, 2026

Gains Report: Can Ironwood Pharmaceuticals Inc stock double in the next yearPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn

Mar 02, 2026
pulisher
Mar 02, 2026

IRWD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 02, 2026
pulisher
Mar 02, 2026

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

IRONWOOD PHARMACEUTICALS INC (IRWD) Earnings History & Surprises - ChartMill

Mar 02, 2026
pulisher
Feb 28, 2026

IRWD Should I Buy - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Plays Key Role In Nasdaq Futures Healthcare - Kalkine Media

Feb 27, 2026
pulisher
Feb 27, 2026

Jefferies Maintains Hold on Ironwood Pharmaceuticals (IRWD) Feb 26, 2026 - Meyka

Feb 27, 2026
pulisher
Feb 26, 2026

A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha

Feb 26, 2026
pulisher
Feb 26, 2026

Jefferies raises Ironwood Pharmaceuticals stock price target on Linzess outlook - Investing.com Canada

Feb 26, 2026
pulisher
Feb 26, 2026

IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Finviz

Feb 26, 2026
pulisher
Feb 26, 2026

IRWD: Analyst Raises Price Target and Maintains Rating | IRWD St - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9.5% on Analyst Upgrade - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00 at Citizens Jmp - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

GSA Capital Partners LLP Has $405,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat

Feb 26, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue - simplywall.st

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood (IRWD) Q4 2025 Earnings Call Transcript - The Globe and Mail

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Balances Growth Plans With Pricing Risks - TipRanks

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highli - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals (IRWD) officer sells shares to cover tax withholding - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-02-25 - Seeking Alpha

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Faces Tumultuous Week Amid Market Volatility - StocksToTrade

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownWhat's Next? - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop - Investing.com Australia

Feb 25, 2026
pulisher
Feb 25, 2026

IRWD: 2026 guidance targets >$1.1B LINZESS sales and pivotal apraglutide Phase III launch - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Form 8K Ironwood Pharmaceuticals Inc For: 25 February By Investing.com - Investing.com Australia

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals (IRWD) Targets Over $300M Adjusted EBIT - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood (IRWD) Reports Q4 Revenue Below Expectations - GuruFocus

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2026 - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals officially released its financial report for the fourth quarter and full year of 2025 today. - Bitget

Feb 25, 2026
pulisher
Feb 25, 2026

IRONWOOD PHARMACEUTICALS ($IRWD) Releases Q4 2025 Earnings - Quiver Quantitative

Feb 25, 2026
pulisher
Feb 25, 2026

Form 8K Ironwood Pharmaceuticals Inc For: 25 February - Investing.com India

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook - The AI Journal

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results - TradingView

Feb 25, 2026
pulisher
Feb 25, 2026

Ironwood Pharmaceuticals (IRWD) posts 2025 results and raises 2026 EBITDA outlook - Stock Titan

Feb 25, 2026
pulisher
Feb 24, 2026

Ironwood: Q4 Financial Overview - Bitget

Feb 24, 2026
pulisher
Feb 24, 2026

Insights into Ironwood Pharmaceuticals's Upcoming Earnings - Benzinga

Feb 24, 2026
pulisher
Feb 24, 2026

Rate Hike: Can Ironwood Pharmaceuticals Inc stock double in the next year2025 Key Lessons & Long-Term Growth Stock Strategies - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 23, 2026

What's in Store for These 5 Medical Companies This Earnings Season? - TradingView

Feb 23, 2026
pulisher
Feb 22, 2026

Ironwood Pharmaceuticals Faces Operational Challenges Following Third-Quarter Earnings - StocksToTrade

Feb 22, 2026
pulisher
Feb 21, 2026

IRWD’s Strategic Moves Amid Market Dynamics - timothysykes.com

Feb 21, 2026

Ironwood Pharmaceuticals Inc (IRWD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ironwood Pharmaceuticals Inc (IRWD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
John Minardo
Chief Legal Officer
Feb 23 '26
Sale
3.81
17,439
66,443
382,939
Shetzline Michael
SVP, CMO, Head-Res&Drug
Feb 23 '26
Sale
3.81
15,570
59,322
538,437
Gaskins Tammi L
Chief Commercial Officer
Feb 24 '26
Sale
3.66
11,239
41,135
213,738
Gaskins Tammi L
Chief Commercial Officer
Feb 23 '26
Sale
3.81
10,287
39,193
224,977
MCCOURT Thomas A
Chief Executive Officer
Feb 24 '26
Sale
3.66
103,526
378,905
1,489,002
MCCOURT Thomas A
Chief Executive Officer
Feb 23 '26
Sale
3.81
94,757
361,024
1,592,528
Martini Gregory S.
Chief Financial Officer
Feb 24 '26
Sale
3.66
11,457
41,933
160,601
Martini Gregory S.
Chief Financial Officer
Feb 23 '26
Sale
3.81
10,487
39,955
172,058
Silver Ronald
Principal Accounting Officer
Feb 24 '26
Sale
3.66
12,621
46,193
252,636
Silver Ronald
Principal Accounting Officer
Feb 23 '26
Sale
3.81
11,552
44,013
265,257
drug_manufacturers_specialty_generic RDY
$14.28
price up icon 0.21%
$24.44
price down icon 1.77%
drug_manufacturers_specialty_generic RGC
$25.45
price up icon 6.09%
$133.44
price up icon 1.75%
$14.71
price down icon 1.21%
$490.21
price down icon 1.69%
大文字化:     |  ボリューム (24 時間):